Investing in biotechs can be a risky business. Success hinges mostly on two criteria; promising data from clinical trials or regulatory approval. Get either of these wrong and the push back from the Street can be brutal. Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). The panel voted 9-3 against the approval of Nuplazid (pimavanserin) as a therapy for hallucinations and delusions associated with Alzheimer’s disease (ADP).
https://www.tipranks.com/news/article/acadia-stock-deep-discount-or-trap-for-investors-analysts-weigh-in?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.